New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week

 
• By Maureen Kenny and Vibha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Fourteen medicines that are in the final stages of the evaluation process at the European Medicines Agency should find out this week whether they will be approved for marketing across the EU.

Time
This CHMP this week decides on the future of some potentially important new drugs • Source: Shutterstock

This week could bring recommendations for marketing approval throughout the EU for several potentially important new medicines including Johnson & Johnson's first-in-class interleukin-23 inhibitor, Tremfya (guselkumab), for the treatment of plaque psoriasis, Roche's new multiple sclerosis treatment, Ocrevus (ocrelizumab), and Tesaro's PARP inhibitor, Zejula (niraparib), for the treatment of ovarian cancer.

Tremfya, Ocrevus and Zejula, all of which were recently approved in the US, are among the 14 marketing authorization applications...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

More from Product Reviews

data

New EU Filings

 
• By Saba Afreen

<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

data

EU CHMP Opinions And MAA Updates

 
• By Saba Afreen

<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>